Gilead Sciences, Inc. (GILD) Position Held by Nations Financial Group Inc. IA ADV
Nations Financial Group Inc. IA ADV maintained its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the SEC. The fund owned 3,050 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Nations Financial Group Inc. IA ADV’s holdings in Gilead Sciences were worth $216,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of GILD. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares during the period. Penserra Capital Management LLC boosted its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares during the period. American Beacon Advisors Inc. purchased a new stake in Gilead Sciences during the 1st quarter valued at about $143,000. Sterling Investment Advisors Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $184,000. Finally, Washington Trust Bank boosted its holdings in Gilead Sciences by 24.8% during the 2nd quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 550 shares during the period. Institutional investors own 74.62% of the company’s stock.
In related news, EVP Gregg H. Alton sold 50,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares in the company, valued at $8,945,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 666,819 shares of company stock valued at $52,303,086 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.44 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a market capitalization of $94,560.00, a price-to-earnings ratio of 7.43, a P/E/G ratio of -1.19 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.
Several brokerages recently weighed in on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a report on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $84.87.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.